Gordan Vujanic FRCPath,MD,PhDSenior Attending Physician Years Of Experience: 37
About the Physician
Dr. Gordan Vujanic is Senior Attending Physician in Pediatric Pathology. He joined Sidra in 2017, and he (together with his team) responsible for delivering pediatric pathology services. I am working on preparation of Sidra joining the international study on renal tumors of childhood.
Prior to joining Sidra, Dr. Vujanic worked as Professor of Pediatric Pathology and consultant pediatric pathologist at University Hospital of Wales / Cardiff University Medical School, Cardiff, U.K. where he established and developed pediatric pathology services for Wales. Dr. Vujanic moved to the UK from Belgrade (Serbia), where he finished his training in pathology and PhD.
Dr. Vujanic has been working in a field of pediatric renal tumors for many years and is Chair of the UK and SIOP (International Society of Pediatric Oncology) Pathology panel for renal tumors of childhood. He introduced and is providing rapid central pathology review for the UK and another 20 countries, which enables children to be treated accurately, avoiding under- or over treatment as it was the case in the past. He is responsible for coordinating work of another 9 national/regional pathology panels around the world and is the principal author of the classification of renal tumors of childhood which has been followed for treatment stratification in the last 20 years in the SIOP trials and studies.
Years Of Experience37 Education
- University Hospital of Wales / Cardiff University Medical School, Cardiff, U.K.
- SIOP and its Executive Committee for renal tumors
- member of the PPS, ESP and IPPA
- fellow of the Royal College of Pathologists (U.K.)
Areas of Interest
- Renal tumours of childhood
- Other tumours in children
- Lecturing around the world, director of international postgraduate courses in paediatric pathology (2017 - )
Medical Publications (selected publications for last 5 years)
- Vujanic GM, Mifsud W, Chowdhury T, Al-Saadi R, Pritchard-Jones K. CHARACTERISTICS AND OUTCOMES OF PREOPERATIVELY TREATED PATIENTS WITH ANAPLASTIC WILMS TUMORS REGISTERED IN THE UK SIOP- WT-2001 AND IMPORT STUDY COHORT (2002-2020) Cancer 2022; DOI 10.1002.CNCR.34107
- Vujanić GM, D'Hooghe E, Graf N, Vokuhl C, Al-Saadi R, Chowdhury T, Pritchard-Jones K, Furtwängler R. Prognostic Significance Of Histopathological Response To Preoperative Chemotherapy In Unilateral Wilms Tumor: An Analysis Of 899 Patients Treated On The SIOP WT 2001 Protocol In The UK CCLG And GPOH Studies. Int J Cancer. 2021;149(6):1332-1340 doi.org/10.1002/ijc.33707.
- Vujanić GM, D'Hooghe E, Vokuhl C, Collini P. Dataset for the reporting of nephrectomy specimens for wilms' tumour treated with preoperative chemotherapy: recommendations from the international society of paediatric oncology renal tumour study group. Histopathology. 2021; doi: 10.1111/his.14394.
- Vujanic GM, D’Hooghe E, Popov SD, Sebire NJ, Kelsey A. THE EFFECT OF PREOPERATIVE CHEMOTHERAPY ON HISTOLOGICAL SUBTYPING AND STAGING OF WILMS TUMORS: THE UNITED KINGDOM CHILDREN’S CANCER STUDY GROUP (UKCCSG) WILMS TUMOUR TRIAL 3 (UKW3) EXPERIENCE. Pediatr Blood Cancer 2018;e27549. doi.org/10.1002/pbc.27549
- Vujanić GM, Gessler M, Ooms AHAG, Collini P, Coulomb-l’Hermine A, D’Hooghe E, de Krijger RR, Perotti D, Pritchard-Jones K, Vokuhl C, van den Heuvel-Eibrink MM, Graf N. POSITION PAPER: The UMBRELLA SIOP-RTSG 2016 Study Wilms tumour pathology and molecular biology protocol Nat Rev Urol. 2018, Nov;15(11):693-701, doi.org/10.1038/s41585-018-0100-3